| 2001 |
JFC1/SYTL1 was identified as a novel tandem C2 domain-containing protein that associates with p67(phox) of the leukocyte NADPH oxidase complex; JFC1 binds p67(phox) but not p47(phox) directly, acting as an adaptor between PI3K products and the oxidase cytosolic complex. JFC1 binds phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 3,4-diphosphate but not inositol 1,3,4,5-tetrakisphosphate, and is restricted to the plasma membrane/secretory vesicle fraction in neutrophils. |
Yeast two-hybrid screen, affinity chromatography pulldown, subcellular fractionation, lipid-binding assay |
The Journal of biological chemistry |
High |
11278853
|
| 2001 |
JFC1/SYTL1 is an ATP-binding protein with magnesium-dependent ATPase activity; it specifically binds ATP analog 8-azido-ATP, hydrolyzes ATP and dATP with Km ~58 µM and kcat 2.27/min, and contains a nucleotide-binding site with unique characteristics distinct from GHKL ATPase/kinase superfamily. PIP3 binding does not affect ATPase kinetics. |
In vitro ATPase assay, photoaffinity labeling with 8-azido-[α-32P]ATP, truncation mutagenesis |
Proceedings of the National Academy of Sciences of the United States of America |
High |
11553774
|
| 2002 |
The C2A domain of JFC1/SYTL1 is solely responsible for binding 3'-phosphorylated phosphoinositides (PIP3) and directing plasma membrane localization in living cells; the C2A domain colocalizes with the PH domain of Akt in vivo, dissociates from membrane upon PI3K inhibition, and its membrane association is modulated by calcium. |
Live-cell imaging with GFP-tagged domain constructs, PI3K inhibitor treatment, co-localization with Akt PH domain, lipid-binding assay |
Proceedings of the National Academy of Sciences of the United States of America |
High |
12189202
|
| 2002 |
The JFC1/SYTL1 promoter contains three functional NF-κB binding sites; NF-κB p50 and p65 bind these sites and transactivate JFC1 expression, and TNFα upregulates JFC1 expression in prostate carcinoma cells through this NF-κB pathway. |
Gel retardation/EMSA, supershift assay, luciferase reporter assay, promoter mutagenesis, dominant-negative IκB expression |
The Biochemical journal |
High |
12137562
|
| 2005 |
JFC1/SYTL1 is phosphorylated by Akt at serine 241; Akt-mediated phosphorylation of JFC1 causes its dissociation from the plasma membrane and redistribution to the cytosol without disrupting the JFC1-Rab27a interaction. JFC1 binding to Rab27a (dependent on W83 of JFC1) reduces Akt phosphorylation of JFC1. |
In vitro kinase assay with constitutively active Akt, mass spectrometry phosphosite identification, site-directed mutagenesis (S241A, W83S), immunoprecipitation, PI3K inhibitor (LY294002) treatment, subcellular localization by immunofluorescence |
Traffic (Copenhagen, Denmark) |
High |
15998322
|
| 2005 |
JFC1/SYTL1 (a Rab27a- and PIP3-binding protein) regulates androgen-dependent secretion of prostatic-specific acid phosphatase (PSAP) but not PSA from LNCaP prostate cells; JFC1 co-localizes with PSAP but not PSA in prostate granules, and both Rab27a and PI3K are required for exocytosis of prostate-specific secretory markers. |
Dominant-negative C2A domain overexpression, JFC1 overexpression, immunofluorescence colocalization, PI3K inhibitor treatment, constitutively active Rab27aQ78L expression, secretion assay |
The Biochemical journal |
High |
16004602
|
| 2008 |
JFC1/SYTL1 and Munc13-4 are Rab27a effectors that regulate exocytosis of distinct neutrophil granule subsets; JFC1 co-localizes with Rab27a in predocked/docked vesicles and specifically regulates azurophilic granule (myeloperoxidase) exocytosis, while Munc13-4 regulates gelatinase B (gelatinase granule) secretion. |
siRNA knockdown, TIRF microscopy, immunofluorescence, genetically modified mice (Munc13-4-deficient Jinx mice), secretion assay for myeloperoxidase and gelatinase B |
Traffic (Copenhagen, Denmark) |
High |
18939952
|
| 2008 |
Slp1/JFC1 and Slp2-a are expressed in cytotoxic T lymphocytes (CTLs), both interact with Rab27a, and both localize predominantly to the plasma membrane of human and mouse CTLs. Slp2-a but not Slp1 is rapidly degraded when Rab27a is absent (due to PEST-like sequences in Slp2-a). Dominant-negative SHD of Slp2-a (56% identical to Slp1 SHD) reduces CTL killing, indicating both contribute to secretory lysosome exocytosis from CTL. |
Expression screening, co-immunoprecipitation with Rab27a, immunofluorescence localization in CTLs, dominant-negative overexpression, cytotoxicity assay |
Traffic (Copenhagen, Denmark) |
Medium |
18266782
|
| 2008 |
Slp1/JFC1 is abundantly expressed in pancreatic acinar cells, interacts with Rab27B in vivo, co-localizes with Rab27B on zymogen granules, and Slp1 knockout mice show increased numbers of zymogen granules, indicating Slp1 is part of the amylase secretion machinery of the exocrine pancreas. |
Immunohistochemistry/immunofluorescence, co-immunoprecipitation, Slp1 knockout mouse analysis, morphological analysis |
Archives of biochemistry and biophysics |
Medium |
18477466
|
| 2012 |
JFC1/SYTL1 associates with the RhoA-GAP protein GMIP (Gem-interacting protein); GMIP downregulation induces RhoA activation and actin polymerization that impairs vesicular transport and exocytosis. JFC1-containing secretory organelles move in actin-free areas near the plasma membrane, and JFC1-knockout neutrophils show increased RhoA activity with azurophilic granules unable to traverse cortical actin. |
Proteomic/mass spectrometry identification, live-cell quantitative microscopy, JFC1 knockout neutrophils, RhoA activity assay, siRNA knockdown of GMIP, actin visualization |
Molecular biology of the cell |
High |
22438581
|
| 2012 |
EPI64 (a TBC-domain RabGAP protein) directly binds to a C-terminal region of JFC1/SYTL1; JFC1 is an effector for Rab8a, and EPI64 recruits Rab8a-GTP via JFC1 for deactivation by EPI64's RabGAP activity, thereby regulating Arf6-dependent membrane trafficking. Mutations that uncouple JFC1 from either EPI64 or Rab8-GTP disrupt vacuole formation phenotype. |
Co-localization, direct binding assay, mutant analysis (RabGAP-dead EPI64, JFC1 uncoupling mutants), co-expression studies, Rab8-GTP level measurement |
Molecular biology of the cell |
High |
22219378
|
| 2019 |
JFC1/SYTL1 controls Rac1-GTP recycling from the neutrophil uropod to promote directional migration; JFC1-null neutrophils show Rac1-GTP accumulation at the uropod and impaired chemotaxis in vitro and in vivo. JFC1 interacts with Rac1-GTP in a Rab27a-independent manner at dynamic vesicles, and STORM super-resolution microscopy shows adjacent distribution of JFC1 and Rac1-GTP that increases upon activation. |
JFC1-null mice, live-cell microscopy, STORM super-resolution microscopy, co-immunoprecipitation (Rac1-GTP and JFC1), in vivo bone marrow chimera neutrophil migration assay, chemotaxis assay, Rac1-GTP localization analysis |
Journal of leukocyte biology |
High |
30748033
|
| 2023 |
LincRNA01703 enhances the interaction between Rab27a, SYTL1/JFC1, and CD81 to promote secretion of CD81+ exosomes; this complex formation suppresses immune cell infiltration in the tumor microenvironment to inhibit lung adenocarcinoma metastasis. |
In vivo metastasis assay, co-immunoprecipitation, exosome secretion assay, lncRNA overexpression/knockdown |
Cancers |
Medium |
38136327
|
| 2023 |
WTAP (m6A writer) promotes YTHDF2-mediated m6A methylation and degradation of SYTL1 mRNA, reducing SYTL1 protein levels in bladder cancer cells and impairing NK cell anti-tumor activity. |
RIP-qPCR, actinomycin D mRNA stability assay, western blot, RT-qPCR, in vivo tumor model |
Histology and histopathology |
Medium |
37933909
|
| 2022 |
ELK1 recruits HDAC2 to the SYTL1 promoter to repress SYTL1 transcription; ELK1 and HDAC2 form a complex that specifically binds the SYTL1 promoter, suppressing SYTL1 expression and promoting bladder cancer malignant phenotype. |
ChIP assay, co-immunoprecipitation, luciferase reporter assay, siRNA knockdown of ELK1/HDAC2, in vitro and in vivo tumor assays |
Human cell |
Medium |
36107384
|
| 2023 |
Rab27a effector JFC1/SYTL1 localizes to Anaplasma phagocytophilum inclusions via its C2A domain binding 3'-phosphoinositides (PI3P enriched in inclusion membrane), mediating docking/fusion of Rab27a-bearing granules with inclusions to promote bacterial proliferation; blocking Rab27a-JFC1 interaction with Nexinhib20 inhibits Anaplasma infection. |
shRNA knockdown, live-cell imaging, immunostaining, dominant-negative C2A domain expression, small-molecule inhibitor (Nexinhib20), infection assay |
Microbes and infection |
Medium |
38110148
|
| 2025 |
Nexinhib20 inhibits JFC1-mediated mobilization of a subset of CD11b+ granules to the plasma membrane, reducing β2-integrin avidity; this effect is JFC1-dependent but Rac1-independent, confirmed by JFC1-KO neutrophils and direct measurement of Rac1 activation by FRET-based assay and Rac1-PAK1 binding assay. |
JFC1-KO mice, Nexinhib20 small-molecule inhibitor, quantitative 3D super-resolution microscopy, FRET-based Rac1 activity assay, Rac1-PAK1 binding assay, flow cytometry |
Journal of leukocyte biology |
High |
39883854
|